Sie befinden sich hier

Inhalt

Prof. Dr. Karen Bieback

EXPERIMENTAL CELL THERAPY

Our focus is the regenerative medicine including the development of new cell-based therapies (advanced therapy medicinal products, ATMP). Within this field, we are mainly interested in mesenchymal stromal cells (MSC) and endothelial precursor cells (EPC).

Cell therapy is a fascinating and highly interdisciplinary field, which integrates various research areas, such as cell biology, immunology, bio-analytics, imaging technologies, medical technology, process development and automation.

Since immunomodulatory mechanisms (see figure) are key for MSC therapeutic efficacy, we aim to better understand these.

Proposed therapeutic mechanism of action of MSC.
From Fiori et al. Immunobiology 2018 https://doi.org/10.1016/j.imbio.2018.01.001

Publications

  • Rendra E, Scaccia E, Bieback K. Recent advances in understanding mesenchymal stromal cells. F1000Res. 2020;9:F1000 Faculty Rev-156. 10.12688/f1000research.21862.1
  • Torres Crigna A, Fricke F, Nitschke K, Worst T, Erb U, Karremann M, Buschmann D, Elvers-Hornung S, Tucher C, Schiller M, Hausser I, Gebert J, Bieback K. Inter-Laboratory Comparison of Extracellular Vesicle Isolation Based on Ultracentrifugation. Transfus Med Hemother. doi:10.1159/000508712)
  • Uhlig S, Wuhrer A, Berlit S, Tuschy B, Sütterlin M, Bieback K. Intraoperative radiotherapy for breast cancer treatment efficiently targets the tumor bed preventing breast adipose stromal cell outgrowth. Strahlenther Onkol. 2020;196(4):398-404. doi: 10.1007/s00066-020-01586-z.688/f1000research.21862.1.
  • Netsch P, Elvers-Hornung S, Uhlig S, Klüter H, Huck V, Kirschhöfer F, Brenner-Weiß G, Janetzko K, Solz H, Wuchter P, Bugert P, Bieback K. Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine. Stem Cell Res Ther. 2018 Jul 4;9(1):184. doi: 10.1186/s13287-018-0936-8.
  • Torres Crigna A, Daniele C, Gamez C, Medina Balbuena S, Pastene DO, Nardozi D, Brenna C, Yard B, Gretz N, Bieback K. Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models. Front Med (Lausanne). 2018 ;5:179. doi: 10.3389/fmed.2018.00179
  • Fiori A, Terlizzi V, Kremer H, Gebauer J, Hammes HP, Harmsen MC, Bieback K. Mesenchymal stromal/stem cells as potential therapy in diabetic retinopathy.Immunobiology. 2018;223(12):729-743. doi: 10.1016/j.imbio.2018.01.001.
  • Hong J, Hueckelhoven A, Wang L, Schmitt A, Wuchter P, Tabarkiewicz J, Kleist C, Bieback K, Ho AD, Schmitt M. Indoleamine 2,3-dioxygenase mediates inhibition of virus-specific CD8(+) T cell proliferation by human mesenchymal stromal cells. Cytotherapy. 2016;18(5):621-9. doi: 10.1016/j.jcyt.2016.01.009.
  • Zeuner M, Bieback K, Widera D. Controversial Role of Toll-like Receptor 4 in Adult Stem Cells. Stem Cell Rev Rep. 2015;11(4):621-34. doi: 10.1007/s12015-015-9589-5.
  • Ketterl N, Brachtl G, Schuh C, Bieback K, Schallmoser K, Reinisch A, Strunk D. A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance. Stem Cell Res Ther. 2015;6:236. doi: 10.1186/s13287-015-0233-8.
  • Mattar P, Bieback K. Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells. Front Immunol. 2015;6:560. doi: 10.3389/fimmu.2015.00560.

Kontextspalte

RenalToolBox

Within the EU-funded Innovative Training Network RenalToolBox Medical Faculty Mannheim is associated with 4 out the 15 projects, 2 ESRs supervised by Prof. K. Bieback, 2 by Prof. Dr N. Gretz. mehr...

DIAMICOM

Within the International resreach training group 1874/2 we are working on SP6 adressing the impact of adipose-derived stromal cells on diabetic retinopathy.

www.umm.uni-heidelberg.de/diamicom/